Search

Thirteen patients with malignant tumors were entered into a phase I trial with recombinant DNA human alpha 2 interferon (IFN alpha 2). The patients were given I.M. escalating doses of IFN alpha 2 ranging from 1-10(6) to 200-10(6) IU with a 72 hours washout between injections. In the majority of the patients, subjective symptoms were noted: fever, headache, chills, nausea, myalgias. Asthenia, anorexia, drowsiness appeared after the highest doses and disappeared without any sequellae. Leucopenia and thrombopenia were seen in 11 out of 13 patients. Hepatocellular toxicity was observed in 9 cases. Cardiac and vascular functions were not impaired by IFN alpha 2. The pharmacokinetic studies showed a maximum serum concentration between 4 and 6 hours after injection and the peak value was directly proportional to the dose. No neutralizing INF alpha 2 serum factor was detected during the treatment. The peak value for serum beta 2 microglobulin occurred 48 hours after and the N.K. activity was variably modified by IFN alpha 2 injections. A major clinical response was observed in 1 case, a minor response in 3 cases and a stabilisation of the disease in 4 cases.

Evaluation of the activity of an enzyme activated by interferon (2'-5' oligo-isoadenylate synthetase or 2-5A synthetase) has been used to determine, in man, the interferon inducing capacity of a fraction isolated from Escherichia coli and Klebsiella pneumoniae, SL04, an immunomodulating agent administrated per os. An increase of the activity of this enzyme has been shown in four out of five volunteers following a single oral administration of 100 mg of SL04. This activation demonstrated in humans confirms the pharmacological results of the interferon induction obtained with SL04 in vivo in mice and in vitro in human cell cultures.